Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

3.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.0K
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

5.7K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
5.7K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

85.4K
Overview
85.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lipoprotein(a) and atherosclerosis risk across estimated glucose disposal rate strata: evaluating synergistic predictive utility.

Lipids in health and disease·2026
Same author

Reproductive toxicity of benzo[α]pyrene: Effects, mechanisms, and perspectives.

Comparative biochemistry and physiology. Toxicology & pharmacology : CBP·2026
Same author

Early Outcomes of Real-World Aortic Valve Replacement With RESILIA Tissue in the Chinese Population.

Clinical cardiology·2026
Same author

Trimethylamine N-Oxide Combined with Phenylacetylglutamine as Potential Biomarkers for Diabetic Kidney Disease.

Diabetes, metabolic syndrome and obesity : targets and therapy·2026
Same author

Kangfuxin solution perianal warm moist compress combined with music therapy for anal fullness after endoscopic treatment of internal hemorrhoids.

Frontiers in medicine·2026
Same author

Clinical clustering identifies MASLD subtypes with distinct longitudinal cardiovascular risks and lipidomic profiles.

Hepatology international·2026

Related Experiment Video

Updated: Mar 7, 2026

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
10:10

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

9.3K

Taming autoimmune thyroiditis: cellular immunomodulation through MSCs, Tregs, and tolDCs.

Ting Peng1, Jiangang Wang1,2,3, Yanhui Lin1

  • 1Health Management Center, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.

Frontiers in Immunology
|March 6, 2026
PubMed
Summary

Tolerogenic cellular therapies show promise for autoimmune thyroiditis (AIT) by restoring immune balance. These treatments, including mesenchymal stem cells (MSCs) and regulatory T cells (Tregs), aim to correct immune dysregulation beyond just managing hypothyroidism.

Keywords:
autoimmune thyroiditiscellular immunomodulationmesenchymal stem cells (MSCs)regulatory T cells (Tregs)tolerogenic dendritic cells (tolDCs)

More Related Videos

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

2.6K
Adenoviral Transduction of Naive CD4 T Cells to Study Treg Differentiation
15:33

Adenoviral Transduction of Naive CD4 T Cells to Study Treg Differentiation

Published on: August 13, 2013

16.5K

Related Experiment Videos

Last Updated: Mar 7, 2026

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
10:10

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

9.3K
Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

2.6K
Adenoviral Transduction of Naive CD4 T Cells to Study Treg Differentiation
15:33

Adenoviral Transduction of Naive CD4 T Cells to Study Treg Differentiation

Published on: August 13, 2013

16.5K

Area of Science:

  • Immunology
  • Endocrinology
  • Cell Therapy

Background:

  • Autoimmune thyroiditis (AIT), including Hashimoto's thyroiditis, is an organ-specific autoimmune disease characterized by inflammation and thyroid dysfunction.
  • Current treatments manage hypothyroidism but do not address the root cause of immune dysregulation.
  • Preclinical models indicate cell-based therapies can reduce inflammation and prevent thyroid damage.

Purpose of the Study:

  • To review recent advancements in tolerogenic cellular therapies for autoimmune thyroiditis (AIT).
  • To explore the potential of these therapies in restoring immune homeostasis and achieving long-term tolerance.
  • To discuss mechanisms beyond symptomatic relief for AIT management.

Main Methods:

  • Review of preclinical models and emerging data on extracellular vesicles and antigen-specific dendritic cell targeting.
  • Analysis of immunomodulatory effects of mesenchymal stem cells (MSCs), regulatory T cells (Tregs), and tolerogenic dendritic cells (tolDCs).
  • Focus on mechanisms like cytokine secretion, metabolic reprogramming, and antigen-specific tolerance induction.

Main Results:

  • Cell-based approaches in experimental autoimmune thyroiditis (EAT) models mitigate inflammation and correct Th17/Treg imbalance.
  • Extracellular vesicles and antigen-specific dendritic cell targeting show potential for immunological reprogramming.
  • MSCs, Tregs, and tolDCs demonstrate multifaceted immunomodulatory effects.

Conclusions:

  • Tolerogenic cellular therapies offer a promising strategy for modifying AIT progression.
  • These therapies aim to restore immune homeostasis and achieve long-term immune tolerance in AIT.
  • Cellular therapies represent a shift from symptomatic treatment to addressing the underlying immune dysregulation in AIT.